Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 3
1987 2
1993 1
1994 1
1997 1
2003 1
2007 1
2008 5
2009 4
2010 6
2011 7
2012 6
2013 2
2014 2
2015 1
2016 9
2017 16
2018 17
2019 13
2020 21
2021 24
2022 12
2023 11
2024 19

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

163 results

Results by year

Filters applied: . Clear all
Page 1
Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.
Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, Tagawa ST, Nordquist LT, Vaishampayan N, El-Haddad G, Park CH, Beer TM, Armour A, Pérez-Contreras WJ, DeSilvio M, Kpamegan E, Gericke G, Messmann RA, Morris MJ, Krause BJ; VISION Investigators. Sartor O, et al. Among authors: rahbar k. N Engl J Med. 2021 Sep 16;385(12):1091-1103. doi: 10.1056/NEJMoa2107322. Epub 2021 Jun 23. N Engl J Med. 2021. PMID: 34161051 Free PMC article. Clinical Trial.
Prostate Cancer Theranostics: PSMA Targeted Therapy.
Seifert R, Alberts IL, Afshar-Oromieh A, Rahbar K. Seifert R, et al. Among authors: rahbar k. PET Clin. 2021 Jul;16(3):391-396. doi: 10.1016/j.cpet.2021.03.004. PET Clin. 2021. PMID: 34053583 Review.
Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT).
Kratochwil C, Fendler WP, Eiber M, Hofman MS, Emmett L, Calais J, Osborne JR, Iravani A, Koo P, Lindenberg L, Baum RP, Bozkurt MF, Delgado Bolton RC, Ezziddin S, Forrer F, Hicks RJ, Hope TA, Kabasakal L, Konijnenberg M, Kopka K, Lassmann M, Mottaghy FM, Oyen WJG, Rahbar K, Schoder H, Virgolini I, Bodei L, Fanti S, Haberkorn U, Hermann K. Kratochwil C, et al. Among authors: rahbar k. Eur J Nucl Med Mol Imaging. 2023 Jul;50(9):2830-2845. doi: 10.1007/s00259-023-06255-8. Epub 2023 May 29. Eur J Nucl Med Mol Imaging. 2023. PMID: 37246997 Free PMC article.
Prostate Cancer Theranostics With 177Lu-PSMA.
Ahmadzadehfar H, Seifert R, Afshar-Oromieh A, Kratochwil C, Rahbar K. Ahmadzadehfar H, et al. Among authors: rahbar k. Semin Nucl Med. 2024 Jul;54(4):581-590. doi: 10.1053/j.semnuclmed.2024.02.007. Epub 2024 Apr 4. Semin Nucl Med. 2024. PMID: 38570288 Free article. Review.
Pulmonary Tuberculosis: Role of Radiology in Diagnosis and Management.
Nachiappan AC, Rahbar K, Shi X, Guy ES, Mortani Barbosa EJ Jr, Shroff GS, Ocazionez D, Schlesinger AE, Katz SI, Hammer MM. Nachiappan AC, et al. Among authors: rahbar k. Radiographics. 2017 Jan-Feb;37(1):52-72. doi: 10.1148/rg.2017160032. Radiographics. 2017. PMID: 28076011 Review.
Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial.
Fizazi K, Herrmann K, Krause BJ, Rahbar K, Chi KN, Morris MJ, Sartor O, Tagawa ST, Kendi AT, Vogelzang N, Calais J, Nagarajah J, Wei XX, Koshkin VS, Beauregard JM, Chang B, Ghouse R, DeSilvio M, Messmann RA, de Bono J. Fizazi K, et al. Among authors: rahbar k. Lancet Oncol. 2023 Jun;24(6):597-610. doi: 10.1016/S1470-2045(23)00158-4. Lancet Oncol. 2023. PMID: 37269841 Free PMC article. Clinical Trial.
EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT).
Kratochwil C, Fendler WP, Eiber M, Baum R, Bozkurt MF, Czernin J, Delgado Bolton RC, Ezziddin S, Forrer F, Hicks RJ, Hope TA, Kabasakal L, Konijnenberg M, Kopka K, Lassmann M, Mottaghy FM, Oyen W, Rahbar K, Schöder H, Virgolini I, Wester HJ, Bodei L, Fanti S, Haberkorn U, Herrmann K. Kratochwil C, et al. Among authors: rahbar k. Eur J Nucl Med Mol Imaging. 2019 Nov;46(12):2536-2544. doi: 10.1007/s00259-019-04485-3. Epub 2019 Aug 22. Eur J Nucl Med Mol Imaging. 2019. PMID: 31440799
Safety and Survival Outcomes of 177Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with Prior 223Ra treatment: The RALU Study.
Rahbar K, Essler M, Pabst KM, Eiber M, Fougère C, Prasad V, Rassek P, Hasa E, Dittmann H, Bundschuh RA, Fendler WP, Kurtinecz M, Schmall A, Verholen F, Sartor O. Rahbar K, et al. J Nucl Med. 2023 Apr;64(4):574-578. doi: 10.2967/jnumed.122.264456. Epub 2022 Oct 27. J Nucl Med. 2023. PMID: 36302656 Free PMC article.
Reply by Authors.
Rachubinski P, Witt JH, Budäus L, Zinke J, Fangmeyer B, Spieker T, Vetterlein M, Rahbar K, Kachanov M, Leyh-Bannurah SR. Rachubinski P, et al. Among authors: rahbar k. J Urol. 2022 Dec;208(6):1213. doi: 10.1097/JU.0000000000002921.04. Epub 2022 Dec 1. J Urol. 2022. PMID: 36349926 No abstract available.
163 results